FDA Clears Rasonque for Pancreatic Cancer at $477,000 a Year
Updated
Updated · Yahoo Finance · Aug 28
FDA Clears Rasonque for Pancreatic Cancer at $477,000 a Year
3 articles · Updated · Yahoo Finance · Aug 28
Summary
Revolution Medicines' oral Rasonque won FDA approval for adults with metastatic pancreatic adenocarcinoma after a phase 3 trial showed a 60% lower risk of death.
13.2 months of survival in the trial compared with 6.7 months on chemotherapy, making the pill a rare life-extending option in a cancer usually found after it has spread.
$39,800 for a 30-day supply sets the wholesale list price at about $477,000 annually—more than double Merck's Keytruda list price, according to BioPharma Dive.
Medicare Part D and other coverage could cut what patients pay, with Revolution saying government discounts may trim 20% to 30% and some commercially insured patients may qualify for $0 copays.
67,000 U.S. cases are expected in 2026, and the FDA called the drug a critical new option for a historically hard-to-treat cancer despite side effects including rash, diarrhea and nausea.
With a price tag reaching hundreds of thousands, will this breakthrough pancreatic cancer pill become an inaccessible luxury?
If this drug conquered the most notoriously undruggable cancer mutation, which terminal disease will this revolutionary science cure next?
Could the very mechanism making this molecular clamp so effective also trigger aggressive new forms of cancer resistance?
FDA Approves Daraxonrasib: First RAS Inhibitor Nearly Doubles Survival in Metastatic Pancreatic Cancer
Overview
On August 26, 2026, the FDA approved daraxonrasib (Rasonque) for adults with metastatic pancreatic cancer who had already received treatment. This decision was based on the RASolute 302 trial, which showed that daraxonrasib nearly doubled survival and slowed disease progression compared to chemotherapy. The drug works by forming a stable tricomplex with mutated RAS protein, blocking tumor growth even in dense tumors. Patients benefit from fewer severe side effects, such as less bone marrow toxicity, and proactive care helps manage skin rashes and mouth sores. With this breakthrough, rapid RAS mutation testing and new combination therapies are becoming essential in cancer care.